- Home
- DCBO vs RCKT Comparison
DCBO vs RCKT Comparison
Compare DCBO & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCBO
- RCKT
- Stock Information
- Founded
- DCBO 2016
- RCKT 1999
- Country
- DCBO Canada
- RCKT United States
- Employees
- DCBO N/A
- RCKT N/A
- Industry
- DCBO
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- DCBO
- RCKT Health Care
- Exchange
- DCBO Nasdaq
- RCKT Nasdaq
- Market Cap
- DCBO 795.1M
- RCKT 764.5M
- IPO Year
- DCBO 2020
- RCKT N/A
- Fundamental
- Price
- DCBO $26.20
- RCKT $2.93
- Analyst Decision
- DCBO Buy
- RCKT Buy
- Analyst Count
- DCBO 6
- RCKT 11
- Target Price
- DCBO $42.50
- RCKT $19.68
- AVG Volume (30 Days)
- DCBO 82.1K
- RCKT 7.8M
- Earning Date
- DCBO 08-07-2025
- RCKT 08-04-2025
- Dividend Yield
- DCBO N/A
- RCKT N/A
- EPS Growth
- DCBO 268.72
- RCKT N/A
- EPS
- DCBO 0.74
- RCKT N/A
- Revenue
- DCBO $222,824,000.00
- RCKT N/A
- Revenue This Year
- DCBO $13.57
- RCKT N/A
- Revenue Next Year
- DCBO $13.40
- RCKT N/A
- P/E Ratio
- DCBO $35.23
- RCKT N/A
- Revenue Growth
- DCBO 16.79
- RCKT N/A
- 52 Week Low
- DCBO $25.50
- RCKT $2.19
- 52 Week High
- DCBO $53.86
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- DCBO 39.12
- RCKT 33.01
- Support Level
- DCBO $26.79
- RCKT $2.73
- Resistance Level
- DCBO $28.20
- RCKT $3.33
- Average True Range (ATR)
- DCBO 0.68
- RCKT 0.30
- MACD
- DCBO 0.13
- RCKT 0.05
- Stochastic Oscillator
- DCBO 0.99
- RCKT 64.63
About DCBO Docebo Inc.
Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.